Although some people with plaque psoriasis can control their symptoms by using topical treatments that are applied to the skin, some people with moderate or severe plaque psoriasis do not get enough ...

Although some people with plaque psoriasis can control their symptoms by using topical treatments that are applied to the skin, some people with moderate or severe plaque psoriasis do not get enough ...

Complete clearance lasts for a very long time due to knockout of resident memory T cells within the skin,’ said the study’s ...

Please provide your email address to receive an email when new articles are posted on . Bimzelx (bimekizumab-bkzx) is the first and only interleukin 17A and 17F inhibitor approved in this indication.

Otezla is the first oral therapy approved for moderate to severe plaque psoriasis in this patient population. The Food and Drug Administration (FDA) has expanded the approval of Otezla ® (apremilast) ...

Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, announced new Phase 3b topline Week 16 results from Cohort A of the VISIBLE trial, the first prospective, large-scale, randomized-controlled ...

Deucravacitinib demonstrated stable or decreased adverse event rates over three years, with sustained clinical efficacy in plaque psoriasis patients. The study included 1519 patients, with 513 ...

A real-world analysis reveals that tildrakizumab is highly effective and safe in patients with moderate-to-severe plaque ...

Bimzelx is available as a single-dose prefilled autoinjector or prefilled syringe containing 160mg/mL of solution. Bimzelx ® (bimekizumab-bkzx) is now available for the treatment of moderate to severe ...

Recent advances in molecular and pathobiology have brought the field of dermatology to the cusp of reaching a goal that seemed highly improbable or impossible just a few years ago: a cure for plaque ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. 100% of patients treated with 150 mg, 300 mg and 600 mg ...

Portia has not taken Sotyktu. Portia Brown* has long been drawn toward helping people cope with challenges. Since volunteering as a college student to work with her peers to educate them about sexual ...